Literature DB >> 15490140

Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage.

Mariann Harangi1, Ildikó Seres, Zsuzsa Varga, Gabriella Emri, Zoltán Szilvássy, György Paragh, Eva Remenyik.   

Abstract

OBJECTIVE: High-density lipoprotein (HDL)-associated antioxidant paraoxonase (PON) may reduce low-density lipoprotein (LDL) oxidation and prevent atherosclerosis. The aim of this present study was to investigate the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor atorvastatin on hydrogen-peroxide-induced DNA damage by comet assay and the correlation between oxidative DNA damage and antioxidant PON activity.
METHODS: Thirteen type-II/a hyperlipidemic patients were enrolled in the study. We examined the effect of 10 mg/day atorvastatin treatment on lipid levels and the degree of DNA damage in lymphocytes separated from hyperlipidemic patients, nitric oxide (NO), thiobarbituric acid-reactive substances (TBARS), PON levels and activity.
RESULTS: After 6 months, atorvastatin treatment significantly decreased serum cholesterol and LDL-cholesterol levels. The triglyceride level did not change, and there was no significant change in the HDL cholesterol level. The visual score characteristic to the degree of DNA damage in comet assay was significantly decreased, as well as the TBARS level, while the level of NO was non-significantly increased. PON activity and the PON/HDL ratio were significantly increased after atorvastatin treatment. There was a negative correlation between DNA damage and PON activity, as well as between DNA damage and the PON/HDL ratio before and after atorvastatin treatment.
CONCLUSION: These findings show that atorvastatin treatment favorably affected the lipid profile, increasing the activity of HDL-associated PON and decreasing the cytotoxic effect of oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15490140     DOI: 10.1007/s00228-004-0820-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Statins promote potent systemic antioxidant effects through specific inflammatory pathways.

Authors:  Mehdi H Shishehbor; Marie-Luise Brennan; Ronnier J Aviles; Xiaoming Fu; Marc S Penn; Dennis L Sprecher; Stanley L Hazen
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

Review 2.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

3.  Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.

Authors:  R Hoffman; G J Brook; M Aviram
Journal:  Atherosclerosis       Date:  1992-03       Impact factor: 5.162

Review 4.  Is paraoxonase related to atherosclerosis.

Authors:  M I Mackness; S Arrol; C A Abbott; P N Durrington
Journal:  Chem Biol Interact       Date:  1993-06       Impact factor: 5.192

5.  Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.

Authors:  D D Cilla; L R Whitfield; D M Gibson; A J Sedman; E L Posvar
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

6.  Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients.

Authors:  Q Zhu; J McMaster; D Mymin; T Dembinski; G Hatch; P C Choy; E A Kroeger
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

7.  Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.

Authors:  R C Sorenson; C L Bisgaier; M Aviram; C Hsu; S Billecke; B N La Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

8.  Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.

Authors:  N A Le; W Innis-Whitehouse; X Li; R Bakker-Arkema; D Black; W V Brown
Journal:  Metabolism       Date:  2000-02       Impact factor: 8.694

9.  Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies.

Authors:  M Aviram; G Dankner; U Cogan; E Hochgraf; J G Brook
Journal:  Metabolism       Date:  1992-03       Impact factor: 8.694

10.  A comparative study of the in vitro antioxidant activity of statins.

Authors:  Ferdinando Franzoni; Alfredo Quiñones-Galvan; Francesco Regoli; Ele Ferrannini; Fabio Galetta
Journal:  Int J Cardiol       Date:  2003-08       Impact factor: 4.164

View more
  15 in total

1.  Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients.

Authors:  Hamiyet Donmez-Altuntas; Fahri Bayram; Ayse N Coskun-Demirkalp; Osman Baspınar; Derya Kocer; Peter P Toth
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-19

Review 2.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

3.  Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

Authors:  Beatrice A Golomb; Edwin K Kwon; Sabrina Koperski; Marcella A Evans
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  The Relationship between Cancer and Paraoxonase 1.

Authors:  Irma Martha Medina-Díaz; Néstor Ponce-Ruíz; Aurora Elizabeth Rojas-García; José Francisco Zambrano-Zargoza; Yael Y Bernal-Hernández; Cyndia Azucena González-Arias; Briscia S Barrón-Vivanco; José Francisco Herrera-Moreno
Journal:  Antioxidants (Basel)       Date:  2022-03-31

5.  Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice.

Authors:  S V V S Ramanjaneyulu; P P Trivedi; S Kushwaha; A Vikram; G B Jena
Journal:  J Physiol Biochem       Date:  2013-02-06       Impact factor: 4.158

6.  Strenuous physical exercise accelerates the lipid peroxide clearing transport by HDL.

Authors:  Iiro A Välimäki; Timo Vuorimaa; Markku Ahotupa; Tommi J Vasankari
Journal:  Eur J Appl Physiol       Date:  2016-07-01       Impact factor: 3.078

7.  A Therapeutic Effects of Atorvastatin on Genetic Damage in Coronary Artery Disease.

Authors:  Kishore Kumar Gundapaneni; Nivas Shyamala; Rajesh Kumar Galimudi; Sanjib Kumar Sahu; Surekha Rani Hanumanth
Journal:  J Clin Diagn Res       Date:  2016-06-01

8.  Improving Total-Cholesterol/HDL-Cholesterol Ratio Results in an Endothelial Dysfunction Recovery in Peripheral Artery Disease Patients.

Authors:  Silvia Bleda; Joaquín de Haro; César Varela; Leticia Esparza; Javier Rodriguez; Francisco Acin
Journal:  Cholesterol       Date:  2012-09-25

9.  PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

Authors:  Jordi Camps; Anabel García-Heredia; Anna Rull; Carlos Alonso-Villaverde; Gerard Aragonès; Raúl Beltrán-Debón; Esther Rodríguez-Gallego; Jorge Joven
Journal:  PPAR Res       Date:  2012-01-24       Impact factor: 4.964

10.  Evaluation of Maternal Serum 25-Hydroxyvitamin D, Paraoxonase 1 Levels, and Neutrophil-to-Lymphocyte Ratio in Spontaneous Preterm Birth.

Authors:  Ozlem Bozoklu Akkar; Enver Sancakdar; Savas Karakus; Caglar Yildiz; Ismail Akkar; Murat Arslan; Irfan Oguz Sahin; Ayse Gonca Imir Yenicesu; Ali Cetin
Journal:  Med Sci Monit       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.